Evidence map›Paper›PMID 38864383›Full record

ArticleJournal of medicinal chemistry2024

Colloidal Aggregation Confounds Cell-Based Covid-19 Antiviral Screens.

Isabella S Glenn, Lauren N Hall, Mir M Khalid, Melanie Ott, Brian K Shoichet

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Library Docking for Cannabinoid-2 Receptor Ligands.Journal of medicinal chemistry · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Library docking for Cannabinoid-2 Receptor ligands.bioRxiv : the preprint server for biology · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Isabella S GlennDepartment of Pharmaceutical Chemistry, University of California San Francisco (UCSF), San Francisco, California 94143, United States.
Lauren N HallDepartment of Pharmaceutical Chemistry, University of California San Francisco (UCSF), San Francisco, California 94143, United States.
Mir M KhalidGladstone Institutes, San Francisco, California 94158, United States.ORCID 0000-0002-1862-6795
Melanie OttGladstone Institutes, San Francisco, California 94158, United States.
Brian K ShoichetDepartment of Pharmaceutical Chemistry, University of California San Francisco (UCSF), San Francisco, California 94143, United States.ORCID 0000-0002-6098-7367

Funding

Targeting Viroporins and Coronavirus M ProteinU19AI171110 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI James Solomon Fraser · 2022 to 2026
$103.4M
Development and Testing of New Computational Methods for Ligand Discovery and MechanismR35GM122481 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Brian K Shoichet · 2017 to 2026
$8.5M
NIAID NIH HHS U19 AI171110NIGMS NIH HHS R35 GM122481
6 · The paper itself

Abstract

Colloidal aggregation is one of the largest contributors to false positives in early drug discovery. Here, we consider aggregation's role in cell-based infectivity assays in Covid-19 drug repurposing. We investigated the potential aggregation of 41 drug candidates reported as SARs-CoV-2 entry inhibitors. Of these, 17 formed colloidal particles by dynamic light scattering and exhibited detergent-dependent enzyme inhibition. To evaluate the impact of aggregation on antiviral efficacy in cells, we presaturated the colloidal drug suspensions with BSA or spun them down by centrifugation and measured the effects on spike pseudovirus infectivity. Antiviral potencies diminished by at least 10-fold following both BSA and centrifugation treatments, supporting a colloid-based mechanism. Aggregates induced puncta of the labeled spike protein in fluorescence microscopy, consistent with sequestration of the protein on the colloidal particles. These observations suggest that colloidal aggregation is common among cell-based antiviral drug repurposing and offers rapid counter-screens to detect and eliminate these artifacts.

Indexed as

Antiviral AgentsColloidsSARS-CoV-2COVID-19COVID-19 Drug TreatmentDrug RepositioningHumansSpike Glycoprotein, CoronavirusAntiviral AgentsColloidsSpike Glycoprotein, Coronavirus

Identifiers

PMID38864383
PMCPMC11236530

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.